Expert Rev Anti Infect Ther. 2013;11(12):1333-1353. Form in which it is administered CMS (inactive pro-drug), slow and incomplete conversion to colistin (active moiety) Polymyxin B sulfate (active ...
7d
BioVersys Announces First Patient First Visit in HABP/VABP Pivotal Phase 3 RIV-TARGET Trial of BV100
BV100 is a potential best-in-class anti-infective agent in treating hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP) caused by carbapenem-resistant ...
A randomized trial involving gram-negative bacterial bloodstream infections found that rapid antibiotic susceptibility ...
What is the mechanism of the carbapenem and valproic acid drug interaction, and what should clinicians do to minimize patient risk? 1. Decreased absorption of VPA secondary to inhibition of intestinal ...
CAMBRIDGE, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) and GSK plc (LSE/NYSE: GSK) today announced efficacy and safety results of the positive pivotal phase 3 ...
The research team led by Professor Qu investigated the intrahost evolution of carbapenem-resistant Klebsiella pneumoniae (CRKP) ST11 by collecting a series of K. pneumoniae strains isolated from a ...
Please provide your email address to receive an email when new articles are posted on . Cefepime-enmetazobactam demonstrated superiority compared with piperacillin-tazobactam in a phase 3 trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results